Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics Inc (KYMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,488,906
  • Shares Outstanding, K 81,642
  • Annual Sales, $ 39,210 K
  • Annual Income, $ -311,350 K
  • EBIT $ -349 M
  • EBITDA $ -350 M
  • 60-Month Beta 2.20
  • Price/Sales 162.74
  • Price/Cash Flow N/A
  • Price/Book 4.02

Options Overview Details

View History
  • Implied Volatility 67.70% (-3.90%)
  • Historical Volatility 43.38%
  • IV Percentile 51%
  • IV Rank 19.60%
  • IV High 153.30% on 12/05/25
  • IV Low 46.82% on 08/18/25
  • Expected Move (DTE 17) 7.38 (8.86%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 185
  • Volume Avg (30-Day) 69
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 2,555
  • Open Int (30-Day) 2,580
  • Expected Range 75.91 to 90.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.89
  • Number of Estimates 10
  • High Estimate $-0.71
  • Low Estimate $-1.03
  • Prior Year $-0.82
  • Growth Rate Est. (year over year) -8.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
73.31 +13.61%
on 03/24/26
91.00 -8.47%
on 03/02/26
-8.06 (-8.82%)
since 02/27/26
3-Month
66.21 +25.81%
on 01/20/26
95.90 -13.15%
on 02/26/26
+1.97 (+2.42%)
since 12/26/25
52-Week
19.44 +328.45%
on 04/09/25
103.00 -19.14%
on 12/08/25
+53.67 (+181.20%)
since 03/28/25

Most Recent Stories

More News
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting

Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and...

KYMR : 83.29 (+4.79%)
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting

WATERTOWN, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

KYMR : 83.29 (+4.79%)
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated...

KYMR : 83.29 (+4.79%)
Kymera Therapeutics to Participate in Upcoming March Investor Conferences

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

KYMR : 83.29 (+4.79%)
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

WATERTOWN, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

KYMR : 83.29 (+4.79%)
Kymera Therapeutics to Participate in Upcoming February Investor Conferences

WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

KYMR : 83.29 (+4.79%)
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027...

KYMR : 83.29 (+4.79%)
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial...

KYMR : 83.29 (+4.79%)
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13

WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

KYMR : 83.29 (+4.79%)
Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks

Institutional insiders are placing big bets on DASH, KVUE, and KYMR. See how much is being spent on these three stocks and which investors are buying.

KYMR : 83.29 (+4.79%)
KMB : 96.47 (+0.12%)
KVUE : 17.24 (unch)
DASH : 150.15 (+1.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States.

See More

Key Turning Points

3rd Resistance Point 92.03
2nd Resistance Point 89.04
1st Resistance Point 86.17
Last Price 83.29
1st Support Level 80.31
2nd Support Level 77.32
3rd Support Level 74.45

See More

52-Week High 103.00
Last Price 83.29
Fibonacci 61.8% 71.08
Fibonacci 50% 61.22
Fibonacci 38.2% 51.36
52-Week Low 19.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.